The Missing Middle in Male Fertility: Why the Gap Between Diagnosis and IVF Matters

For much of its history, fertility care has followed a relatively straightforward pathway: identify the problem, determine the available options and move to assisted reproductive technology when necessary.

For millions of couples, treatments such as IUI and IVF have been transformative, but there is another part of the fertility pathway that deserves more attention: the space between identifying a male fertility issue and escalating to advanced reproductive treatment.

I think of it as the “missing middle” of male fertility.

This is not an argument against IVF. It is an argument for a more complete fertility-care ecosystem—one that recognizes male reproductive health as an important part of diagnosis, treatment, laboratory practice and innovation.

Male fertility is part of the healthcare pathway

Male factors contribute, in whole or in part, to infertility in approximately half of infertile couples. Yet fertility care can still become disproportionately focused on the female partner, particularly as couples move toward treatment. That matters beyond the individual patient.

How thoroughly we evaluate and address male reproductive health can influence treatment decisions, patient experience, laboratory utilization, healthcare costs and ultimately the demand placed on assisted reproductive technologies. A more comprehensive approach starts by recognizing male fertility as part of the couple's reproductive health equation from the beginning.

There is more to male fertility than a semen analysis

Semen analysis remains an essential starting point. Concentration, motility and morphology provide important information about the sperm population, but sperm are living cells with complex biological functions. Measuring how many sperm are present, how they move and what they look like does not necessarily tell us everything about why a couple is experiencing infertility or how those sperm will function. This creates room for a broader male fertility pathway.

Depending on the patient and underlying cause, that pathway might include better diagnostics, medical or surgical treatment, lifestyle interventions, fertility preservation, sperm preparation and selection, and emerging reproductive-health technologies.

The goal should not be to add more tests or interventions simply because we can. The more useful question is: Can better information or a better intervention change a clinical decision, improve the patient journey or create meaningful value within the healthcare system?

The laboratory is an important part of the opportunity

One area I believe deserves particular attention is the fertility laboratory. IVF has already created sophisticated infrastructure across clinics, embryology laboratories and ART workflows. That means innovation does not always require creating an entirely new treatment pathway.

Sometimes the opportunity is to improve what is already happening. Better diagnostics, automation, sperm selection, laboratory media and improvements in sperm preparation could potentially make existing processes more effective or efficient.

For innovators, that presents an important question, “Can we improve a laboratory process in a way that is scientifically meaningful, operationally practical and economically viable?” An innovation may create value by improving efficiency, reducing processing time, integrating into an existing workflow, improving consistency or potentially contributing to better reproductive outcomes, but promising laboratory findings are only the beginning.

Better laboratory results must lead to better evidence

Male fertility innovation faces an important challenge: the distance between a laboratory endpoint and a patient outcome. Improved sperm motility may be biologically interesting. Reduced DNA fragmentation may be meaningful. A new sperm-selection approach may show promise. But those findings alone do not establish that a technology improves pregnancy or live-birth outcomes and that is why validation matters.

A responsible development pathway should move from:

Biological hypothesis → laboratory evidence → independent validation → clinical evidence → adoption.

This is important not only for scientists, but also for investors, healthcare providers and potential commercial partners evaluating new reproductive-health technologies. The question should never be simply, “Does this produce an impressive laboratory result?”, but rather, “Does the evidence support meaningful biological, clinical or operational value?”

Where Aqua Fem fits

At Aqua Fem, our work is focused on a novel compound being investigated for use in sperm-washing media and its potential effect on sperm motility and function during laboratory preparation. Our early findings have been encouraging, but we also recognize that promising data are part of a larger process.

The questions that matter now are the same ones that should be asked of any emerging reproductive-health technology:

Can the findings be independently reproduced? Can the technology integrate into existing laboratory workflows? Can the biological effect translate into meaningful clinical value? And can it ultimately create value for patients, laboratories and organizations delivering fertility care?

Those questions are why continued validation is so important.

Filling the missing middle

The future of male fertility care does not need to be framed as an alternative to IVF. It can be better male fertility evaluation + appropriate intervention + better laboratory science + ART when needed.

For healthcare providers, that means more comprehensive care pathways. For laboratories, it creates opportunities to improve existing processes. For innovators and investors, it opens a broader field of unmet needs. And for couples, it means recognizing both partners as part of the fertility journey from the beginning.

The next phase of fertility innovation may not come from replacing the systems we have already built, but rather improving the spaces between them. Male reproductive health is one of those spaces—and it deserves much more attention.